Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

HyOrc (OTCID: HYOR) Advances Green Methanol Platform as Demand and Economics Align Across European Markets

January 16, 2026

How Innovation and Technology Are Reshaping Pharmaceutical Manufacturing: Key Insights

January 16, 2026

Strategic Insights: Leveraging Compliance and Nutritional Innovations in the Infant Formula Ingredients Market

January 16, 2026

B.C. premier downplays RCMP report linking Indian government to Bishnoi gang

January 16, 2026

City of Kelowna says ‘new faces’ may be contributing to ongoing crime

January 16, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference
Press Release

Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference

By News RoomFebruary 8, 20242 Mins Read
Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference
Share
Facebook Twitter LinkedIn Pinterest Email
Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Cell BioEngines, Inc., a biotechnology company focused on the development of ‘off-the-shelf’ ‘non-gene modified’ hematopoietic stem cells and its derived immune cell therapies for cancer patients, today announced that Dr. Ajay Vishwakarma, Founder and CEO of Cell BioEngines, will be presenting at the BIO CEO & Investor Conference at 2:00 p.m. EST on Monday, February 26, 2024.

“We are thrilled to receive a complimentary registration ticket sponsored by New York City Economic Development Corporation (NYCEDC) under Emerging Innovator’s Track,” said Ajay Vishwakarma, DMD, MSc, MBA. “At the BIO CEO & Investor Conference, I’ll will be highlighting Cell BioEngines’ recent developments on its novel stem cell and immune cell therapies for hard-to-treat blood and solid cancers, ongoing pipeline progress, clinical trial updates, and anticipated milestones”, he added.

Details about the presentation are as follows:

Presenter: Dr. Ajay Vishwakarma, Founder and CEO of Cell BioEngines
Date: Monday, February 26, 2024, at 2:00 p.m. EST
Location: Plymouth room, Marriott Marquis, New York, NY
Registration: Here

Add To Calender: Here

In its 26th year, BIO CEO is one of the largest investor conferences in the life science industry. Cell BioEngines will be available for in person and virtual partnering meetings. Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering.

About Cell BioEngines

Cell BioEngines, Inc., is a clinical-stage biotech company focused on developing ‘off-the-shelf’ allogenic cell therapies as ‘drugs’ to turn all cancers into curable diseases. The company leverages its proprietary Stem–SPACE™ platform technology to produce clinical-grade cells at economies of scale. The company’s versatile platform and pipeline allows them to pursue a broad range of cell and gene therapy product candidates in therapeutic areas of interest with high clinical and commercial potential.

For more information about Cell BioEngines, and to learn more about Dr. Vishwakarma’s presentation and the latest Company developments, please visit www.cellbioengines.com

 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/410c8a90-eda5-4537-bae3-dbb64dd7a610

 


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

HyOrc (OTCID: HYOR) Advances Green Methanol Platform as Demand and Economics Align Across European Markets

How Innovation and Technology Are Reshaping Pharmaceutical Manufacturing: Key Insights

Strategic Insights: Leveraging Compliance and Nutritional Innovations in the Infant Formula Ingredients Market

1024EX Launches Testnet Beta on January 15, 2026: Prediction Market Meets Onchain Trading

Flare Research Reveals that Nearly Half of All Cybercriminals Use Multi-Brand Combo Kits to Steal Data

Nothing to See Here: Nearly Half of Employees Hide Their AI Use at Work

Strongsville Welcomes New Aqua-Tots Swim School, Designed with Families in Mind

Former Altera CEO Sandra Rivera Assumes Role as VSORA’s Chair of the Board

Chomps Partners with Ikon Pass to Meet Consumers on the Mountain as Official Protein Partner

Editors Picks

How Innovation and Technology Are Reshaping Pharmaceutical Manufacturing: Key Insights

January 16, 2026

Strategic Insights: Leveraging Compliance and Nutritional Innovations in the Infant Formula Ingredients Market

January 16, 2026

B.C. premier downplays RCMP report linking Indian government to Bishnoi gang

January 16, 2026

City of Kelowna says ‘new faces’ may be contributing to ongoing crime

January 16, 2026

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

1024EX Launches Testnet Beta on January 15, 2026: Prediction Market Meets Onchain Trading

January 16, 2026

Okanagan Humane Society swamped with dog rescues two weeks into 2026

January 16, 2026

B.C. schoolchildren excused from class with note from prime minister

January 15, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version